The study demonstrates that combining GPX4 inhibitor with PARP inhibitor elicits synergistic efficacy in homologous recombination proficient ovarian cancer cells, distinguishing this mechanism from the ferroptosis pathway. Here, GPX4 is linked to ovarian carcinoma.